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Summary
 
The interaction of the T cell receptor (TCR) with its cognate peptide–major histocompatibil-
ity complex (MHC) on the surface of antigen presenting cells (APCs) is a primary event during
T cell activation. Here we used a dimeric IE
 
k
 
-MCC molecule to study its capacity to activate
antigen-specific T cells and to directly analyze the role of CD4 in physically stabilizing the
TCR–MHC interaction. Dimeric IE
 
k
 
-MCC stably binds to specific T cells. In addition, im-
mobilized dimeric IE
 
k
 
-MCC can induce TCR downregulation and activate antigen-specific T
cells more efficiently than anti-CD3. The potency of the dimeric IE
 
k
 
-MCC is significantly en-
hanced in the presence of CD4. However, CD4 does not play any significant role in stabilizing
peptide-MHC–TCR interactions as it fails to enhance binding of IE
 
k
 
-MCC to specific T cells
or influence peptide-MHC–TCR dissociation rate or TCR downregulation. Moreover, these
results indicate that dimerization of peptide-MHC class II using an IgG molecular scaffold sig-
nificantly increases its binding avidity leading to an enhancement of its stimulatory capacity
while maintaining the physiological properties of cognate peptide–MHC complex. These pep-
tide-MHC–IgG chimeras may, therefore, provide a novel approach to modulate antigen-spe-
cific T cell responses both in vitro and in vivo.
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T
 
he critical initiating event in T cell activation involves
delivery of signal 1 through the TCR. It is now ap-
preciated that TCR signaling involves multiple compo-
nents occurring at the interface between the APC and T
cell membranes in order to initiate optimal intracellular sig-
naling cascades. First and foremost, TCR signaling is criti-
cally dependent on the affinity of the TCR–peptide-MHC
interaction. Surface plasmon resonance studies of TCR’s
interactions with peptide-MHC molecules indicate that
while the overall range of affinities of stimulatory ligands is
low relative to antibody–antigen interactions, it needs to be
sufficiently high (
 
.
 
10
 
2
 
5
 
 M) to induce T cell activation.
MHC-peptide ligands with affinities 
 
,
 
10
 
2
 
5
 
 M can func-
tion as antagonists or may fail to generate any response in T
cells at all (1).
It is well known that multimerization of TCR and CD3
molecules can trigger T cell activation. The experiments
demonstrating this include cross-linking with antibodies
against TCR or cross-linking chimeric molecules consist-
ing of a non-TCR extracellular domain linked to the
CD3
 
z
 
 cytoplasmic dimer (2, 3). In addition, work with T
cells specific for fluorescein or arsonate has shown that acti-
vation of these T cells requires at least dimerization of the
TCR molecules (4–6). The mechanism by which TCRs
are cross-linked under natural circumstances of peptide-
MHC recognition is unclear although several studies sug-
gest an intrinsic capability of MHC molecules to multimer-
ize under certain conditions (7, 8).
Recent evidence has shown that individual peptide-
MHC complexes on APC can serially engage multiple
TCRs, thereby allowing a relatively small number of ap-
propriate peptide-MHC complexes to engage a large pro-
portion of TCRs on cognate T cells (9). Serial TCR en-
gagement presumably allows for the accumulation of signal
towards a critical threshold for T cell activation. This
threshold has been estimated to require serial engagement
of 8,000 TCRs in the absence of CD28 engagement and
roughly 1,500 TCRs in the presence of CD28 engagement
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(10). According to this model, there is no strict require-
ment for TCR multimerization during T cell activation.
Further work is needed to clarify the role of TCR cross-
linking and serial engagement in T cell activation.
Association of the CD4 and CD8 coreceptors with en-
gaged TCR represents an additional process that dramati-
cally affects TCR signaling and T cell activation (2). Re-
cruitment of the coreceptor to the occupied TCR complex
allows cytoplasmically associated Lck to tyrosine phosphor-
ylate CD3
 
z
 
 and/or 
 
z
 
-associated proteins, thereby helping
to initiate a kinase signaling cascade (11). Indirect evidence
has implicated the coreceptors in modulating additional
components of signal 1 generation including stabilization
and/or multimerization of the peptide-MHC–TCR com-
plex as well as TCR downregulation associated with serial
TCR engagement (11–14). Defining the interaction be-
tween the coreceptors and these different parameters of
TCR signaling will provide an enhanced ability to effi-
ciently manipulate antigen-specific T cell responses.
Production of soluble MHC and TCR molecules has
markedly increased our understanding of the basic mecha-
nism of T cell recognition through crystallographic and
biophysical studies (1). However, the low affinity of these
molecules for cognate ligands has limited their usefulness in
studying the interactions of the TCR with other surface
molecules that act in concert to produce immune responses
or in tracking antigen-specific T cells in vivo. To over-
come the low-affinity problem, multivalent peptide–MHC
class I ligands have been generated recently and have been
used successfully for visualization of antigen-specific T cells
in several different systems (15–17).
In this study we examined the capacity of a dimeric pep-
tide–MHC class II–IgG chimera to bind to and activate
cognate T cell lines. We found that, in contrast to mono-
meric peptide–MHC class II, the dimeric peptide–MHC
class II–IgG complexes bound stably and specifically to
cognate T cells. Further analyses showed that peptide-
MHC class II–IgG was significantly more potent than anti-
CD3 at stimulating cognate T cells due to its ability to re-
cruit CD4 into the engaged TCR complex as well as to
more effectively induce TCR downregulation. Analysis of
matched CD4-positive and CD4-negative subclones using
these peptide-MHC class II–IgG molecules allowed us to
directly evaluate the role of the CD4 coreceptor in T cell
activation. In contrast to previous suggestions, our data
showed that the CD4 coreceptor played no apparent role
in either enhancing the stability of TCR–peptide-MHC
interactions or in mediating TCR downregulation.
 
Materials and Methods
 
Mice.
 
C57BL/6 
 
3
 
 SJL founder AND transgenic (Tg)
 
1
 
 mice,
specific for moth cytochrome C peptide (MCC 91–103) in the
context of IE
 
k
 
, backcrossed to B10.BR (H-2
 
k
 
) mice for six to
eight generations, were bred and maintained in the animal care
facility at the Cancer Center of the Johns Hopkins School of
Medicine (18, 19).
 
T Cell Hybridomas and IL-2 Production.
 
The two hybridomas
used in this study were a generous gift of Drs. Kappler and Mar-
rack (National Jewish Medical and Research Center, Denver,
CO). 5KC73.8 is specific for MCC 91–103 in the context of IE
 
k
 
(20). DO11.10 is specific for chicken ovalbumin peptide (cOVA
327–339) in the context of IA
 
d
 
 (21). Since 5KC73.8 cells have a
tendency to lose expression of the CD4 molecule, limiting dilu-
tions were used to obtain a CD4-positive (No. 9) and a CD4-
negative (No. 10) clone of the hybridoma. These two clones ex-
pressed similar levels of TCR.
For stimulation assays, wells of Immulon
 
4
 
 microtiter plates
(Dynatech Laboratories Inc., Chantilly, VA) were coated with
different proteins in PBS overnight at 4
 
8
 
C. Plates were then
washed and coated with 10% FCS for 1 h. Wells coated with mo-
nomeric IE
 
k
 
-MCC, dimeric IE
 
k
 
-MCC (described below), or
anti-CD3 mAb were then used to activate T cell hybridomas at a
density of 5 
 
3
 
 10
 
4
 
 cells per well. After overnight incubation at
37
 
8
 
C, IL-2 was measured using an ELISA minikit (Endogen,
Cambridge, MA).
 
Production of Soluble Dimeric MHC Class II IE
 
k
 
-MCC Protein.
 
Soluble monomeric IE
 
k
 
 covalently linked to the MCC 91–103
peptide was produced and purified as described before (22).
Dimeric IE
 
k
 
-MCC was produced by inserting the cDNA encod-
ing the extracellular domains of the IE
 
a
 
 and 
 
b
 
 chain upstream of
the IgG light and heavy chains, respectively. A Kpn1 restriction
site and a linker were inserted immediately 3
 
9
 
 to the interface be-
tween the extracellular and transmembrane domains of IE
 
b
 
polypeptide. The 5
 
9
 
 regions of the gene had been modified al-
ready to encode the MCC peptide and an EcoR1 restriction site.
The IE
 
a
 
 chain was modified by introduction of a HindIII restric-
tion site immediately 3
 
9
 
 to the codon at the interface between the
extracellular and transmembrane domains. Soluble proteins were
produced in a baculovirus expression system and purified on
14.4.4.S (anti-IE
 
a
 
k
 
) affinity column as described previously (22).
 
Antibodies and Flow Cytometric Analysis.
 
The following anti-
bodies were used in this study: H597 and 2C11 mAbs specific for
murine TCR C
 
b
 
 chain and CD3
 
e
 
, respectively, were produced
following standard techniques. Fluoresceinated RM4-5 specific
for mouse CD4 and biotin-A85-1 specific for murine IgG1 were
purchased from PharMingen (San Diego, CA) whereas PE-
labeled goat anti–mouse IgG1 was purchased from Southern Bio-
tech. Association, Inc. (Birmingham, AL). 14.4.4.S mAb specific
for the 
 
a
 
 chain of IE
 
k
 
 molecule was purified from culture super-
natant using a protein A affinity column.
Cells (2 
 
3
 
 10
 
5
 
) were incubated with a saturating dose of mo-
nomeric IE
 
k
 
-MCC or dimeric IE
 
k
 
-MCC in 100 
 
m
 
l of staining
buffer on ice for 2 h. Cells were then washed, and bound dimeric
IE
 
k
 
-MCC was detected by PE-conjugated goat anti–mouse IgG1,
or biotin-A85-1 mAb followed by PE-streptavidin conjugate, re-
spectively. For detection of TCR and CD4 levels, cells were in-
cubated with biotinylated H597 for 30 min. Cells were then
washed and incubated with PE-conjugated streptavidin and fluo-
resceinated RM4-5 for 20 min on ice followed by analysis by
FACScan
 
Ò
 
 (Becton Dickinson, Mountain View, CA).
 
In Vitro Proliferation Assays.
 
Single cell suspensions from
spleens of AND 
 
3
 
 B10.BR Tg mice were harvested and cultured
at 2.5 
 
3
 
 10
 
5
 
 in 96-well Immulon
 
4
 
 microtiter plates that contained
various concentrations of immobilized monomeric IE
 
k
 
-MCC,
dimeric IE
 
k
 
-MCC, or anti-CD3. Cultures were incubated in 200 
 
m
 
l
of CTM (complete tissue culture medium) at 37
 
8
 
C for 72 h and
 
1
 
Abbreviation used in this paper:
 
 Tg, transgenic. 
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then pulsed with 1 
 
m
 
Ci of 
 
3
 
H-TdR for 6–12 h. Cultures were
then harvested and 
 
3
 
H-TdR uptake was determined by scintilla-
tion counting. Results are expressed as the mean of triplicate cul-
tures (background subtracted).
 
Measurement of TCR Downregulation.
 
The CD4-positive and
CD4-negative clones of the 5KC73.8 T cell hybridoma were in-
cubated with varying concentrations of immobilized monomeric
IE
 
k
 
-MCC, dimeric IE
 
k
 
-MCC, or anti-CD3 in CTM for 5 h at
37
 
8
 
C. Control cells were incubated in parallel cultures in PBS.
All cultures were then recovered and stained, as described above,
with anti-C
 
b
 
 mAb H597 to determine the level of TCRs that re-
mained on the cell surface after stimulation. Results were ex-
pressed as percentages of TCRs on surfaces of the PBS-stimulated
control clones.
 
Effect of CD4 on Binding of IE
 
k
 
-MCC Dimer to 5KC73.8
Clones.
 
Various concentrations of IE
 
k
 
-MCC dimer were incu-
bated with 2 
 
3
 
 10
 
5
 
 cells on ice for 2 h. Cells were washed and
bound dimer was detected by PE-labeled goat anti–mouse IgG1
antibodies. As a control, tested clones were stained with anti-
TCR
 
b
 
 (H597) and anti-CD4 (RM4-5) to confirm the level of
TCR and CD4 at the time of each experiment.
To study the effect of CD4 on dissociation of the dimeric IE
 
k
 
-
MCC from 5KC 73.8 cells, various concentrations of soluble
dimer were incubated with the CD4-positive (No. 9) and the
CD4-negative (No. 10) clones for 2 h on ice. All cultures were
then placed at 4
 
8
 
C, washed once, and resuspended in 180 
 
m
 
l of
staining buffer for the indicated period of time at 4
 
8
 
C. Cells were
immediately washed at 4
 
8
 
C and the bound dimer was detected
using PE-conjugated goat anti–murine IgG1, as described above.
 
Results
 
Stable and Specific Binding of Dimeric IE
 
k
 
-MCC to Specific T
Cells.
 
We used the well characterized I-E
 
k
 
 restricted
MCC system to study T cell activation by dimeric peptide–
MHC complexes. Using IgG as a molecular scaffold we ex-
pressed a soluble IE
 
k
 
-MCC dimer. For the production of
this chimeric molecule, two chimeric genes were con-
structed and introduced into a baculovirus transfer vector.
The first chimeric gene linked DNA encoding the extra-
cellular domains of IE
 
k
 
 
 
a
 
 gene to the 5
 
9
 
 end of a gene en-
coding the mature Ig light chain. The second chimeric
gene linked DNA encoding the extracellular domains of
IE
 
k
 
 
 
b
 
 gene to the 5
 
9
 
 end of a gene encoding the mature Ig
heavy chain. The 5
 
9
 
 sequences of the 
 
b
 
 chain had been al-
tered already by the addition of DNA sequences encoding
the antigenic peptide MCC 91–103 via an alanine/glycine
encoded linker (22). The constructs were cloned into the
dual promoter baculovirus expression vector and used to
infect Sf9 cells. Infected cells produced 
 
z
 
0.5 mg of chi-
meric protein per liter of culture. A monomeric IE
 
k
 
-MCC,
which utilized the same MCC 91–103 peptide and a linker
sequence as the dimeric IE
 
k
 
-MCC, was used for compara-
tive purposes (22).
We first sought to determine whether dimeric IE
 
k
 
-MCC
would bind stably and specifically to MCC-specific T cells.
For these purposes, we used the IE
 
k
 
 
 
1
 
 MCC-specific T
cell hybridoma, 5KC73.8, and, as a specificity control, the
IA
 
d
 
 1 cOVA-specific T cell hybridoma, DO11.10. Analy-
sis by flow cytometry showed significant binding of
dimeric IEk-MCC to 5KC73.8 T cell hybridoma. No
binding of the dimeric IEk-MCC to control DO11.10 T
cell hybridoma was detected although it expressed a high
level of TCR, comparable to those expressed by the
5KC73.8 T cell hybridoma (Fig. 1, a and b). Not surpris-
ingly, there was no stable binding of monomeric IEk-MCC
to either 5KC73.8 or to DO11.10 T cell hybridomas at all
doses tested (data not shown). Therefore, dimerization of
IEk-MCC on the IgG scaffold augmented affinity signifi-
cantly, allowing for binding to cognate T cells that was de-
tectable by flow cytometry.
Dimeric IEk-MCC Is a Potent T Cell Stimulatory Mole-
cule. We next compared the ability of monomeric IEk-
MCC, dimeric IEk-MCC, and anti-CD3 to activate MCC-
specific T cells. To assay T cell stimulation, the different
molecules were coated at varying concentrations onto wells
of Immulon4 plates and used to stimulate IL-2 release by
the MCC-specific T cell hybridoma. Both monomeric
IEk-MCC and dimeric IEk-MCC stimulated specific IL-2
release by 5KC73.8 T cells, but with considerably different
potency (Fig. 2). Dimeric IEk-MCC was significantly bet-
ter at stimulating the 5KC73.8 T cell hybridoma than mo-
nomeric IEk-MCC. At least 40-fold, or more, immobilized
monomeric IEk-MCC was required to achieve a similar re-
sponse as that elicited by the dimer. Interestingly, dimeric
IEk-MCC was even more potent than divalent anti-CD3
mAb, by z5–10-fold. As a negative control, we showed
that DO11.10 T cell hybridoma responded to anti-CD3
mAb but not to either monomeric IEk-MCC or dimeric
Figure 1. Specific binding of the dimeric IEk-MCC to 5KC73.8 T cell
hybridoma. (a) Binding of the IEk-MCC dimer to the 5KC73.8 T cell
hybridoma but not to the negative control, DO11.10 T cell hybridoma.
Cells were incubated with 100 ml of 100 mg/ml of the dimer for 2 h on
ice. Cells were then washed, and bound dimer was detected using biotin-
A85-1 followed by PE-conjugated streptavidin. (b) Both 5KC37.8 and
DO11.10 T cell hybridomas express high levels of TCR. Cells were
stained with a saturating amount of biotin-H597 for 2 h on ice and bound
antibody was detected with PE-streptavidin conjugate.1636 T Cell Activation by Dimeric Peptide–MHC II/IgG
IEk-MCC, confirming the specificity of these molecules for
their cognate TCR.
The stimulatory capacity of the dimeric IEk-MCC was
also evident using naive untransformed T cells from MCC-
specific AND transgenic mice (Fig. 3 a). Under these
conditions, immobilized monomeric IEk-MCC was the
least stimulatory for T cells, while dimeric IEk-MCC was
roughly 10-fold more stimulatory than anti-CD3. No sig-
nificant activation of splenocytes from naive B10.BR mice
was observed using monomeric or dimeric IEk-MCC, in-
dicating the response was antigen specific (data not shown).
An additional advantage of the dimeric IEk-MCC mole-
cules is their ability to bind through the Fc portion of the
IgG to FcR1 splenocytes and activate specific T cells. As
expected, the soluble dimer added to splenocytes from
AND 3 B10.BR Tg mice elicited strong IL-2 response,
comparable to that induced by anti-CD3, whereas a small
amount of IL-2 was produced in response to the soluble
monomer (Fig. 3 b).
Recent experiments indicate that T cell response corre-
lates in magnitude and kinetics with the downregulation of
the TCR (10, 23). To further compare the physiological
properties of monomeric IEk-MCC, dimeric IEk-MCC,
and anti-CD3, the capacity of immobilized forms of these
complexes to induce TCR downregulation of the CD4-
positive clone of 5KC73.8 T cell hybridoma was tested.
We found that dimeric IEk-MCC was more efficient than
anti-CD3 in triggering TCR downregulation (Fig. 4 a).
However, we did not observe any significant downregula-
tion of TCRs in response to the immobilized monomer at
concentrations sufficient to induce IL-2 production by
5KC73.8 T cell hybridoma. Whether failure of monomeric
IEk-MCC to induce TCR downregulation is due to re-
duced sensitivity of the assay or multimerization is needed
for this process requires further investigation. On the other
hand, only anti-CD3, but not monomeric IEk-MCC or
dimeric IEk-MCC, was able to effectively induce TCR
downregulation of the specificity control DO11.10 T cell
hybridoma (Fig. 4 b). Thus, the enhanced stimulatory ca-
pacity of dimeric IEk-MCC correlates very well with its
ability to downregulate TCR associated with serial triggering.
The Enhanced T Cell Stimulation by Dimeric IEk-MCC Is
Partly Mediated by the CD4 Molecule. Engagement of CD4
by the MHC class II molecules is necessary for optimum T
cell response to specific antigens. If this is the reason behind
the enhanced potency of IEk-MCC relative to anti-CD3,
then responses of the 5KC73.8 T cell hybridoma to
dimeric IEk-MCC, but not to anti-CD3, should signifi-
cantly diminish when the CD4 effect is removed. To test
Figure 2. Specific and vigor-
ous response of 5KC73.8 T cell
hybridoma to the dimeric IEk-
MCC. 5KC73.8 cells (left) and
DO11.10 cells (right) were incu-
bated overnight at 378C with
various concentrations of immo-
bilized monomeric IEk-MCC,
dimeric IEk-MCC, or anti-CD3.
IL-2 produced was measured as
described in Materials and Meth-
ods. Results are expressed as the
mean of duplicate cultures. This
experiment is representative of at
least three experiments with sim-
ilar results.
Figure 3. Stimulation of splenocytes from AND Tg mice with immo-
bilized and soluble dimeric IEK-MCC. (a) Splenocytes from AND 3
B10.BR Tg mice were incubated for 72 h at 378C with various concen-
trations of immobilized monomeric IEK-MCC, dimeric IEK-MCC, or
anti-CD3. Cultures were pulsed with 3H-TdR for 12 h at 378C and up-
take was measured by scintillation counting. Results are expressed as the
mean of triplicate cultures (background was subtracted). (b) Strong re-
sponse of splenocytes from AND Tg mice to soluble IEK-MCC dimer.
Splenocytes from AND 3 B10.BR Tg mice were incubated for 48 h at
378C with various concentrations of soluble monomeric IEK-MCC,
dimeric IEK-MCC, or anti-CD3. IL-2 present in culture supernatants was
measured using ELISA. Results are expressed as the mean of triplicate
cultures. One of three experiments with similar results is shown.
Figure 4. Dimeric IEk-MCC triggers TCR downregulation more effi-
ciently than anti-CD3. (a) The CD4-positive clone of 5KC73.8 T cell
hybridoma was incubated with various concentrations of immobilized
monomeric IEK-MCC, dimeric IEK-MCC, or anti-CD3 in CTM for 5 h
at 378C. Cells were then washed and stained with biotin-H597 as de-
scribed in Materials and Methods. It is noteworthy to mention that bind-
ing of dimeric IEk-MCC to 5KC73.8 T cell hybridoma does not block
binding of H597 mAb. Results are expressed as a percentage of TCR that
remained on surface of cells stimulated with PBS-coated wells. (b) Anti-
CD3, but not dimeric IEk-MCC, induced downregulation of the TCR
of the control D011.10 hybridoma. Experiments were performed as de-
scribed in a. This experiment is representative of at least three experi-
ments with similar results.1637 Hamad et al.
this hypothesis, CD4-positive (No. 9) and CD4-negative
(No. 10) clones of the 5KC73.8 T cell hybridoma that ex-
pressed identical levels of TCRs were isolated (Fig. 5 a).
Dose–response curves of these clones to all immobilized
antigens (monomeric IEk-MCC, dimeric IEk-MCC, and
anti-CD3) were significantly shifted to the right in the ab-
sence of CD4, indicating that the 5KC73.8 T cell hybri-
doma response to MCC antigen is CD4 dependent (Fig. 5
b). Interestingly, dimeric IEk-MCC was more potent than
anti-CD3 only when used to stimulate the CD4-positive
clone. However, when the CD4-negative clone was stimu-
lated, the dimeric IEk-MCC and anti-CD3 elicited equiva-
lent responses. This result also indicates that dimerization of
MHC class II by IgG scaffold does not interfere with CD4/
MHC binding as manifested by the major impact of CD4
on the ability of dimeric IEk-MCC, but not anti-CD3, to
activate specific T cells. Thus, it appears that the enhanced
stimulatory capacity of dimeric IEk-MCC, relative to anti-
CD3, depends on its ability to recruit the CD4 coreceptor
to engaged TCR complexes.
CD4 Does Not Stabilize TCR–peptide-MHC Complex In-
teractions or Alter TCR Downregulation. The ability to di-
rectly measure binding of dimeric IEk-MCC to the T cell
surface, as well as the finding that 5KC73.8 T cell hybri-
doma activation is CD4 dependent, allowed us to examine
the role of CD4 in stabilizing TCR–MHC class II–peptide
binding. A potential adhesion role for CD4 has been de-
rived from indirect functional data and from cell–cell adhe-
sion assays using B cells expressing high levels of MHC
class II and fibroblasts transfected with supraphysiological
levels of CD4 (12, 13, 24). In addition, some structural
models have implicated the CD4 molecule in binding and
multimerizing TCR–MHC-peptide complexes (7).
To determine if CD4 can enhance binding of soluble
dimeric IEk-MCC to 5KC73.8 cells, we compared binding
of various concentrations of dimeric IEk-MCC to the CD4-
positive and CD4-negative 5KC73.8 clones. The binding
of IEk-MCC to both the CD4-positive and CD4-negative
5KC73.8 clones was virtually identical at all concentrations
tested (Fig. 6 a). The binding specificity was confirmed by
the failure of the dimer to bind to the negative control,
DO11.10 T cell hybridoma. Similar results were obtained
with cells stained with dimeric IEk-MCC at 378C (data not
shown). Consistent with this binding data, we did not see
any significant difference in the rate of dissociation of the
dimer from the CD4-positive and CD4-negative clones of
5KC73.8 (Fig. 6 b). These results demonstrated that CD4
does not play any significant role in physically stabilizing
TCR–MHC-peptide complexes even though it is required
for optimum T cell activation.
We next examined the influence of the CD4 molecule
on TCR downregulation, a phenomenon that has been
used recently to measure T cell activation (9). We reasoned
that if CD4 binding to TCR–peptide-MHC complex is
required, then removal of CD4 should delay or inhibit an-
tigen-induced TCR downregulation. Therefore, the ability
of dimeric IEk-MCC to induce TCR downregulation in
the presence or absence of the CD4 molecule was deter-
mined. The results in Fig. 7 showed that both the CD4-
positive and CD4-negative 5KC73.8 clones downregulated
their TCR to the same extent, regardless of the level of
CD4 expression. We conclude that antigen-induced TCR
downregulation, at least in this system, can occur in a
CD4-independent manner.
Discussion
In this study, a dimeric peptide–MHC class II molecule
was made, its capacity to bind and activate antigen-specific
T cells was analyzed, and then it was used to directly exam-
ine the adhesion role of the CD4 coreceptor. We demon-
strated that dimeric IEk-MCC could stably bind to cognate
T cells and efficiently stimulate them due to its ability to
cross-link TCR, engage CD4 molecule, and induce serial
Figure 5. (a) Isolation of CD4-
positive and CD4-negative clones
of 5KC73.8 T cell hybridoma.
5KC73.8 T cell hybridoma was
cloned by limiting dilution. A
CD4-positive (No. 9) and a
CD4-negative (No. 10) clone of
5KC73.8 T cell hybridoma that
expressed almost identical levels
of TCRs were selected. (b) CD4
expression significantly enhances
the response of 5KC73.8 T cell
hybridoma to dimeric IEK-MCC
but not to anti-CD3. IL-2 pro-
duced by the CD4-positive clone
No. 9 (top) and the CD4-negative
clone No. 10 (bottom) incubated
with various concentrations of
immobilized monomeric IEK-
MCC, dimeric IEK-MCC, or anti-CD3 was measured as described in the legend for Fig. 2. Monomeric IEK-MCC elicited an IL-2 response from only the
CD4-positive but not the CD4-negative clone, whereas dimeric IEK-MCC induced IL-2 responses by both the CD4-positive and CD4-negative clones.
However, dimeric IEK-MCC was z10-fold better than anti-CD3 at stimulating the CD4-positive clone. Results are expressed as the mean of duplicate cul-
tures. A representative of three experiments with similar results is shown.1638 T Cell Activation by Dimeric Peptide–MHC II/IgG
TCR triggering. In addition, we found that CD4 did not
play a significant adhesion function as it failed to enhance
binding of IEk-MCC to specific T cell hybridoma, in-
fluence MHC-TCR dissociation rate, or influence TCR
downregulation.
The MCC system has been used widely to study pep-
tide-MHC class II interactions with specific T cells. Nu-
merous T cell hybridomas that recognize MCC in the con-
text of IEk have been made and affinity of their soluble
TCRs for IEk-MCC has been measured. Generally, the af-
finity of specific TCRs for IEk-MCC complex is weak,
with Kds in between 30 and 90 mM (1, 25). This low affin-
ity has made it difficult to study and visualize binding of
soluble peptide–MHC class II complexes to specific T cells.
Dimerization of IEk-MCC by the immunoglobulin scaffold
significantly increased the avidity of the complex resulting
in stable binding detectable by flow cytometry. Affinity
measurements of dimeric MHC class I complexed with
several peptides recognized by the dimeric 2C TCR indi-
cate that dimerization increase avidity by z50-fold, both in
cases of alloreactive and cognate ligands (15). Analogous to
our IEk-MCC binding results presented here, peptide-
MHC class I–IgG dimers bind stably and specifically to
CD8 T cells and have been used to detect HTLV-1–spe-
cific T cells from the peripheral blood of HTLV-1–associ-
ated myelopathy patients (16). Therefore, it is conceivable
that the stable binding we see with our IEk-MCC dimers
reflects geometric features of the immunoglobulin hinge
region that confer flexibility to the MHC arms that allow it
to both bind and activate antigen-specific T cells.
Dimeric IEk-MCC was more efficient than anti-CD3 at
inducing serial engagement presumably because, as previ-
ously suggested, the high binding avidity of anti-CD3
hampers its ability to serially engage the TCR (10). Inter-
estingly, dimerization of MHC class II with an IgG scaffold
increases MHC-peptide avidity for the TCR without ef-
fectively interfering with serial engagement. More impor-
tantly, the dimerization of IEk-MCC does not appear to
block the MHC–CD4 interaction as manifested by the
ability of CD4 to increase the T cell response to the
dimeric IEk-MCC but not to anti-CD3. Consequently,
dimeric IEk-MCC are more potent than monomeric IEk-
MCC and anti-CD3 to activate specific T cells.
A potential role for CD4 in stabilizing the binding of
peptide-MHC complexes with the TCRs on the T cell
surface has been derived from indirect functional data and
cell–cell adhesion assays (12, 13, 24). In this report we
showed that stable binding of the dimer to specific T cells
was independent of CD4 expression. Furthermore, the dis-
sociation of peptide-MHC class II from T cell is CD4 in-
dependent. The fact that the response of 5KC73.8 to IEk-
MCC is CD4 dependent, especially at low antigen dose,
and the generally low affinity of T cells for MCC antigen
provide stringent conditions that should have allowed us to
unmask any significant adhesion property of the CD4 mol-
ecule.
Our observation that TCR downregulation induced by
dimeric IEk-MCC is CD4 independent contrasts with the
result of Viola et al., who found that peptide-MHC–medi-
ated TCR downregulation was inhibited by the addition of
antibodies against CD4 (14). However, interpretation of
the anticoreceptor antibody blocking studies is probably
complicated by the potential direct effect of the antibody-
mediated coreceptor cross-linking. In addition, in the same
study the authors found that inhibitors of p56lck kinase
blocked T cell activation but not TCR downregulation,
indicating that TCR downregulation can be dissociated
from T cell activation. This latter result is consistent with our
observation that lack of CD4 expression significantly im-
paired the ability of 5KC73.8 T cell hybridoma to produce
IL-2 (Fig. 5 b), but not to downregulate its TCR (Fig. 7).
Several previous reports have concluded indirectly that
CD4 has a minimal adhesion effect. For example, Weber
Figure 6. (a) CD4 does not enhance the binding of soluble dimeric
IEK-MCC to 5KC73.8 T cell hybridoma. The CD4-positive and the
CD4-negative clones of 5KC73.8 T cell hybridoma, as well as the control
DO11.10 T cell hybridoma were incubated with various doses of soluble
dimeric IEK-MCC for 2 h at 48C. Cells were then washed, and bound
dimer was detected using PE-conjugated goat anti–mouse IgG1. This ex-
periment is representative of at least three experiments with similar results.
(b) The CD4 molecule does not significantly influence dissociation of the
IEk-MCC dimer from 5KC73.8 T cell hybridoma. Various concentra-
tions of soluble dimer were incubated with CD4-positive and CD4-nega-
tive clones for 2 h on ice. Cells were then washed once and resuspended
in 180 ml of staining buffer and incubated for the indicated period of time
at 48C. Cells were then immediately washed at 48C and a saturating dose
of PE-conjugated streptavidin goat anti–mouse IgG1 was used to detect
bound dimer by FACScanÒ.
Figure 7. TCR downregula-
tion induced by the immobilized
dimer is not influenced by CD4
molecule expression. The CD4-
positive and CD4-negative
clones of 5KC73.8 T cell hybri-
doma were incubated with vari-
ous concentrations of the immo-
bilized dimer for 5 h. The
percentage of TCR that re-
mained on the cell surface after
stimulation was determined as
described in the legend to Fig. 4.
This experiment is representative
of at least three experiments with
similar results.1639 Hamad et al.
and Karjalainen (26) had estimated the affinity of CD4 for
MHC to be ,104 M21 and concluded that it was too low
to mediate any adhesion function. Glaichenhaus et al. (27)
reported that CD4 plays a minor adhesion function, based
on their finding that only a small amount of IL-2 was pro-
duced by T cells expressing mutant CD4 molecule that
could not bind p56lck. In addition, Davis et al. (1), using
BIAcore analysis, were not able to detect any increase in
the affinity of soluble TCR for its cognate peptide–MHC
complex in the presence of soluble CD4 molecule. Never-
theless, the failure to detect enhancement of TCR–pep-
tide-MHC binding by CD4 does not rule out a potential
role for it in facilitating cross-linking of TCR–peptide-
MHC complexes through lateral interactions at the T cell–
APC interface or in cases of other less potent antigens such
as partial agonist and antagonists peptides.
In contrast to the CD4 molecule, the adhesion function
of the CD8 molecule has been demonstrated recently by
two different groups. Luescher et al. (28) showed that ex-
pression of CD8 could significantly enhance binding of sol-
uble MHC class I to specific T cells as measured by flow
cytometry. On the other hand Garcia et al. (29) showed
that the addition of soluble CD8 molecule increased the af-
finity of soluble TCR for its cognate peptide–MHC class I
complex by z10-fold. This functional difference between
the CD4 and CD8 molecules should not be that surprising
given the fundamental structural and biochemical differ-
ence between these two molecules. The CD8 molecule is a
heterodimer and usually is associated with only small num-
bers of p56lck molecules. On the other hand, CD4 is mo-
nomeric and usually is associated with as many as 10 times
the amount of p56lck as that associated with the CD8 mole-
cule (30). Therefore, it is possible that CD4 functions as a
signal transducing molecule more than as an adhesion mol-
ecule and the opposite may be true for the CD8 molecule.
The experimental system described here outlines a gen-
eral approach for using divalent high affinity ligands to dis-
sect out the role of MHC class II engagement in activation
of antigen-specific T cells. We found an enhanced potency
of the peptide-MHC class II–IgG chimera, relative to anti-
CD3, in stimulating T cells. This enhanced potency ap-
pears to be due to both the ability of dimeric IEk-MCC to
recruit the coreceptor to engaged TCR and to more effi-
ciently mediate serial engagement and cross-linking of TCR.
The ability to efficiently stimulate antigen-specific T cells,
even when added to cultures in soluble rather than a plate-
bound form, attests to the multifaceted usage of such mole-
cules. These features make peptide-MHC–IgG chimeras
exciting new tools to modulate antigen-specific T cell re-
sponses.
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Note added in proof. Recently, Crawford et al. observed no effect of CD4 on binding of tetrameric MHC class
II MHC covalent peptide complexes to cognate T cells. (Crawford, F., H. Kozono, J. White, P. Marrack,
and J. Kappler. 1998. Immunity. 8:675–682.)
References
1. Davis, M., J. Boniface, Z. Reich, D. Lyons, J. Hampl, B.
Arden, and Y. Chien. 1998. Ligand recognition by ab T cell
receptors. Annu. Rev. Immunol. 16:523–544.
2. Janeway, C. 1992. The T cell receptor as a multicomponent
signaling machine: CD4/CD8 coreceptors and CD45 in T
cell activation. Annu. Rev. Immunol. 10:645–674.
3. Davis, M.M. 1995. Serial engagement proposed. Nature.
375:104.
4. Rao, A., W.W. Ko, S. Faas, and H. Cantor. 1984. Analogs
that compete for antigen binding to an arsonate reactive T
cell clone inhibit the functional response to arsonate. Cell.
36:879–888.
5. Symer, D., R. Dintzis, D. Diamond, and H. Dintzis. 1992.
Inhibition or activation of human T cell receptor transfec-
tants is controlled by defined, soluble antigen arrays. J. Exp.
Med. 176:1421–1430.
6. Abastado, J., Y. Lone, A. Casrouge, G. Boulot, and P. Kouril-
sky. 1995. Dimerization of soluble major histocompatibility
complex–peptide complexes is sufficient for activation of T
cell hybridoma and induction of unresponsiveness. J. Exp.
Med. 182:439–447.
7. Wu, H., P. Kwong, and W. Hendrickson. 1997. Dimeric as-
sociation and segmental variability in the structure of human
CD4. Nature. 387:527–530.
8. Reich, Z., J. Boniface, D. Lyons, N. Borochov, E. Wachtel,
and M. Davis. 1997. Ligand specific oligomerization of T cell
receptor molecules. Nature. 387:617–620.
9. Valitutti, S., S. Muller, M. Celia, E. Padovan, and A. Lanza-
vecchia. 1995. Serial triggering of many T cell receptors by a
few peptide-MHC complexes. Nature. 375:148–161.1640 T Cell Activation by Dimeric Peptide–MHC II/IgG
10. Viola, A., and A. Lanzavecchia. 1996. T cell activation deter-
mined by T cell receptor number and tunable thresholds. Sci-
ence. 273:104–106.
11. Madrenas, J., L.A. Chau, J. Smith, J. Bluestone, and R.N.
Germain. 1997. The efficiency of CD4 recruitment to ligand
engaged TCR controls the agonist/partial agonist properties
of peptide-MHC molecule ligands. J. Exp. Med. 185:219–229.
12. Marrack, P., R. Endres, R. Shimonkevitz, A. Zlotnik, D.
Dialynas, F. Fitch, and J. Kappler. 1983. The major histo-
compatibility complex restricted antigen receptor on T cells.
II. Role of the L3T4 product. J. Exp. Med. 158:1077–1091.
13. Gay, D., P. Maddon, R. Sekaly, M. Talle, M. Godfrey, E.
Long, G. Goldstein, L. Chess, R. Axel, J. Kappler, and P.
Marrack. 1987. Functional interaction between human T cell
protein CD4 and the major histocompatibility complex
HLA-DR antigen. Nature. 328:626–629.
14. Viola, A., M. Salio, L. Tuosto, S. Linkert, O. Acuto, and A.
Lanzavecchia. 1997. Quantitative contribution of CD4 and
CD8 to T cell antigen receptor serial triggering. J. Exp. Med.
186:1775–1779.
15. O’Herrin, S., M. Lebowitz, J. Bieler, B. al-Ramadi, U. Utz,
A. Bothwell, and J. Schneck. 1997. Analysis of the expression
of peptide–major histocompatibility complexes using high af-
finity soluble divalent T cell receptors. J. Exp. Med. 186:
1333–1345.
16. Greten, T., J. Slansky, R. Kubota, S. Soldan, E. Jaffee, T.
Leist, D. Pardoll, S. Jacobson, and J. Schneck. 1998. Direct
visualization of antigen specific T cells: HTLV-1 Tax11-19
specific CD81 T cells are activated in peripheral blood and
accumulate in cerebrospinal fluid from HAM/TSP patients.
Proc. Natl. Acad. Sci. USA. 95:27568–27573.
17. Altman, J., P. Moss, P. Goulder, D. Barouch, M. Mcheyzer-
Williams, J. Bell, A. McMichael, and M. Davis. 1996. Phe-
notypic analysis of antigen specific T lymphocytes. Science.
274:94–96.
18. Kaye, J., M.-L. Hsu, M.-E. Sauron, S.C. Jameson, N.R. Gas-
coigne, and S. Hedrick. 1989. Selective development of
CD41 T cells in transgenic mice expressing a class II MHC
restricted antigen receptor. Nature. 341:746–749.
19. Cauley, L., K. Cauley, F. Shub, G. Huston, and S. Swain.
1997. Transferable anergy: superantigen treatment induces
CD41 T cell tolerance that is reversible and requires CD42
CD82 cells and interferon g. J. Exp. Med. 186:71–81.
20. White, J., A. Pullen, K. Choi, P. Marrack, and J. Kappler.
1993. Antigen recognition of mutant Vb 31 T cell receptor
are consistent with an immunoglobulin like structure for the
receptor. J. Exp. Med. 177:119–125.
21. Gay, D., C. Coeshott, W. Golde, J. Kappler, and P. Marrack.
1986. The major histocompatibility complex restricted anti-
gen receptor on T cells. IX. Role of accessory molecules in
recognition of antigen plus isolated IA. J. Immunol. 136:
2026–2032.
22. Kozono, H., J. White, J. Clements, P. Marrack, and J. Kap-
pler. 1994. Production of soluble MHC class II proteins with
covalently bound single peptides. Nature. 369:151–154.
23. Rothenberg, E. 1996. How T cells count. Science. 273:78–79.
24. Dolye, C., and J. Strominger. 1987. Interaction between
CD4 and class II MHC molecules mediated cell adhesion.
Nature. 330:256–259.
25. Liu, C., F. Crawford, P. Marrack, and J. Kappler. 1998. T
cell positive selection by a high density, low affinity ligand.
Proc. Natl. Acad. Sci. USA. 95:4522–4526.
26. Weber, S., and K. Karjalainen. 1992. Mouse CD4 binds MHC
class II with extremely low affinity. Int. Immunol. 5:695–698.
27. Glaichenhaus, N., N. Shastri, D. Littman, and J. Turner.
1991. Requirement for association of P56lck with CD4 in an-
tigen specific signal transduction. Cell. 64:511–520.
28. Luescher, I.F., E. Vivier, A. Layer, J. Mahlou, F. Godeau, B.
Malissen, and P. Romero. 1995. CD8 modulation of T cell
antigen receptor ligand interactions on living cytotoxic T
lymphocytes.  Nature. 373:353–356.
29. Garcia, K., C. Scott, A. Brunmark, F. Carbone, P. Peterson,
I. Wilson, and L. Teyton. 1996. CD8 enhances formation of
stable T cell receptor/MHC class I molecule complexes. Na-
ture. 384:577–581.
30. Maroun, C., and M. Juluis. 1994. Distinct roles of CD4 and
CD8 as coreceptors in T cell receptor signalling. Eur. J. Im-
munol. 24:959–966.